Specialty Pharmacy

The economics of one and done gene therapies dictate a revenue model that requires outcomes-based risk.

The supplemental Biologics License Application was filed based on positive overall survival data from a phase 3 clinical trial for pembrolizumab in the treatment of recurrent or metastatic head and neck squamous cell carcinoma.

There are currently no FDA-approved therapies for the prevention or treatment of acute graft-versus-host disease.

Immunotherapy may become a viable option for patients with cancer infected with HIV.

Top news of the day across the health care landscape.

Robert F. Sidonio Jr, MD, assistant professor of pediatrics at Emory University, Children's Healthcare of Atlanta, discusses how a multi-disciplinary clinic model improves patient care in hemophilia treatment centers.

Analysis finds universal screening for hepatitis C virus infection would be cost effective and provide greater benefit than the currently recommended birth cohort screening.

The study is the longest observation to date of patients with advanced Merkel cell carcinoma receiving first-line pembrolizumab.

A recent model by Massachusetts General Hospital projects that without proper policy, public health and health care delivery efforts, the opioid overdose epidemic will increase.

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

Top news of the day across the health care landscape.

The findings are further evidence of the impact of an active lifestyle on physical health.

Ado-trastuzumab emtansine (Kadcyla) is currently approved for the treatment of patients with HER-2 positive metastatic breast cancer who previously received trastuzumab and a taxane.

The proposed rule aims to encourage drug manufacturers to pass discounts directly to patients and improve transparency in the market.

Top news of the day across the health care landscape.

The risk of a solid subsequent malignant neoplasm is elevated in survivors of childhood Hodgkin lymphoma, according to an extended follow-up of more than 25 years.

Caplacizumab-yhdp (Cablivi, Sanofi) is a targeted treatment designed to inhibit the formation of blood clots in adults with acquired thrombotic thrombocytopenic purpura.

Data from 2 phase 3 trials showed significant improvement in disease activity in patients with moderate-to-severe atopic dermatitis treated with baricitinib (Olumiant).

Researchers at University of Texas Health Science Center at San Antonio studied 28,000 childhood cancer survivors to determine similarities in long-term effects for various chemotherapies.

Top news of the day across the health care landscape.

Injection drug use has been identified as a predominant risk factor for hepatitis C infection and the opioid epidemic has been suggested as a driver of a recent rise in infections.

Medicare Part D patients can face thousands of dollars in out-of-pocket costs for a single specialty tier drug.

Research seeks to uncover the mechanisms underlying the surging rate of Parkinson disease diagnoses.

Top news of the day across the health care landscape.

HIV-positive patients with hepatocellular carcinoma had an adjusted 24% increased hazard of death compared to their HIV-negative peers.

Blockchain, mobile health, and predictive analytics are just a few areas that could improve patient care and enhance the pharmacy industry.

Researchers have identified a link between CXCR4 expression, fibrosis, and immunosuppression in patients with metastatic breast cancer.

Nick Calla, RPh, vice president of Industry Relations at Cardinal Health Specialty Solutions, discusses the key role of specialty pharmacy in supporting patients and the health care team.

Top news of the day across the health care landscape.